36.03 +0.05 (0.14%)
After hours: 7:54PM EDT
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||35.88 - 36.48|
|52 Week Range||29.83 - 36.60|
|PE Ratio (TTM)||26.32|
|Dividend & Yield||1.28 (3.52%)|
|1y Target Est||N/A|
President Trump's healthcare bill may have died in Congress, but that's not stopping him from making changes to Obamacare. Later today, the president is expected to sign an executive order that would let Americans buy insurance across state lines. Yahoo Finance’s Alexis Christoforous and Editor-in-Chief Andy Serwer figure out if the the president’s move will help lower premiums.
The pharmaceutical industry puts the cost of bringing a medicine from invention to pharmacy shelves at $2.7 billion. A new paper says it is 'just' $648 million. Unfortunately for pharmaceutical investors and people fighting to control drug prices, alike, the new number doesn’t stand up scrutiny.
Customers may be starting to shop for over-the-counter drugs in the same way they shop for groceries—with a keener eye for cost and content—and this could be painful for consumer-health companies.
A deal would give the company capital to do more deals but the decision also keeps the company's recently scratched plans to split into two separate companies alive. The division itself had about $3.4 ...
So far in October, of the 22 analysts covering Eli Lilly (LLY), four have suggested a “strong buy,” while ten analysts have suggested a “buy.”
Pharmaceutical third-quarter earnings are nearly upon us, and Guggenheim's Tony Butler and Allen Cha provide their thoughts on the upcoming results. Butler and Cha write that the hurricanes are a factor ...
T here’s been speculation about whether or not Pfizer (PFE) is planning to make a large acquisition, and Guggenheim’s Tony Butler takes on the question, writing that a smart deal could expand the pharma giant’s multiple. Butler notes that Pfizer’s management has stated that it’s aware of the need to create shareholder value, and he believes that the outcome hinges on a number of factors, including any potential tax reform/cash repatriation holiday, as well as clinical trial results. At the moment, Pfizer has a joint venture with Merck (MRK) to develop Bavencio, a PD-L1 antibody, but Butler wonders if it might be willing to step back if the data isn’t supportive, and if it might be willing to acquire a company with a different, PD-1 antibody—again if the data bears it out.
Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.
Markets barely reacted when Gilead Sciences Inc. (NASDAQ:GILD) announced on Sept. 14 that it would buy Kite Pharma, Inc. for $11.9 billion. The slowdown in Gilead’s HCV business is starting to come to an end. The HCV segment will continue adding meaningfully to Gilead’s cash flow, which is money it needs to fund the Kite acquisition.
First, it raised some spinoff speculation. Second, it's in an intriguing tussle with J&J that could affect the biosimilars market for everyone.
Credit Suisse We are not surprised by Pfizer’s announcement [Tuesday] morning that they are exploring strategic options for their Consumer Healthcare business. Based on our recent conversations with the company, it had become clear to us that Pfizer (PFE) management does not see this business as part of their long-term innovative core. After speaking with the company again today and based on their previous transactions, we assume Pfizer will take their usual time and care in exploring all options.
Pharmaceutical giant Pfizer Inc. is reviewing a sale process for its consumer healthcare business. A spin-off is also possible, Pfizer (PFE) noted. The segment is touted as one of the largest over-the-counter health care products businesses in the world, consisting of well-known products that include dietary supplement Emergen-C, Advil, Thermacare, Robitussin and ChapStick.
The CEOs of Procter & Gamble, Honeywell, and Pfizer are all under pressure to split up their companies. The reasons are different but root cause is the same: the rapacious hunger of short-term investors. Procter & Gamble, seller of toothpaste and toilet paper, drew headlines this week by narrowly winning a proxy battle with Nelson…
Just imagine if Pfizer (PFE) is able to sell its consumer products business? In a note published today, Credit Suisse’s Vamil Divan believes that either a sale or a spinoff is a sure thing on the heels of the pharmaceutical giant’s announcement Tuesday that it was weighing options for the business. It was barely a year ago that Pfizer abandoned the long-debated notion of breaking itself up into two separate companies.
Pfizer (PFE) is exploring strategic alternatives for its Consumer Healthcare segment including a partial or a full separation through a spin-off, sale or other transaction.
Pfizer and Honeywell announced plans to hive off major business units, a reminder that spinoffs remain popular with executives as well as investors, who appreciate their long history of outperforming the ...